Humira® identified in Report on Unsupported Price Increases

Oct 8, 2019

The Institute for Clinical and Economic Review releases its report on Unsupported Price Increases, highlighting AbbVie’s Humira® as one of the products with price increases which are unsupported by new clinical evidence. 

Print Page Mail Article